explore -WSS

explore

author：Wikipedia 2025-09-30 22:08:54 - browse：369

BARCELONA, Spain — Some of the patients waiting in the oncology ward of a hospital here, with its green-tiled floor and white walls, had arrived for a newfangled remedy for blood cancers, what’s known as a CAR-T therapy.

The patients were not here for one of the brand-name medicines — a Kymriah or Yescarta — that have shown the power of these cell-based approaches and helped reap their makers hundreds of millions of dollars. Rather, they would be receiving a CAR-T brewed up right here at Hospital Clínic de Barcelona.

Under a special European policy, the CAR-T developed by the hospital’s experts had won regulatory approval in Spain and was reimbursed by the national health system like other authorized medications. The therapy provided another option for patients, all at a price of 89,000 euros ($97,000), roughly a third of the list prices of the CAR-T products from biopharma companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： The United States is paying nearly triple for new Covid vaccines

leisure time

WSS

WHO recommends second malaria vaccine

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

Novo pauses ads for weight loss drug Wegovy amid demand

IVG is promising — but it won’t replace IVF quite yet

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

leisure time

explore

hotspot

How one medical school became remarkably diverse

Mom launches Girl Scout troop for LGBTQ youth in Texas

United colonoscopy coverage change 'may cost lives,' doctors say

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Moonlake's readout produced a cash windfall. Risks remain

Can medical device makers keep up in the race to treat obesity?

Jerome Adams on the need for new antivirals for Covid

The stability of $0 premiums in Medicare Advantage

Activists slam private health insurers over coverage restrictions

RSV injection headlines need to be accurate for good uptake

focus

Millions may soon lose Medicaid when they don't have to

New oral drug delivery patch is modeled after octopus tentacles

Will an HIV vaccine ever be a reality?

Mom launches Girl Scout troop for LGBTQ youth in Texas

Bispecific antibodies are next new thing in cancer immunotherapy

Study points to new risk in gene therapy death of Terry Horgan

explore

leisure time

entertainment

focus